MMMohammad Mousavi

Mohammad Mousavi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohammad Mousavi has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Brain-gut-bone axis; a review of the association between gut microbiota and osteoporosis

    by Sina Salem Ahim, Sara Aghaei, Farzin Banei, Mohammad Mousavi, Mohammad Shahsavan, Kamran Safa, Amin Norouzbeygi, Elahe Zaremoghadam, Faezeh Nesaei

    The brain-gut-bone axis plays a crucial and complex role in regulating bone metabolism, particularly in the context of osteoporosis. This multidirectional communication network integrates signals from several physiological systems, including the gut microbiota, immune system, nervous system, and hormonal environment, all of which collectively influence the balance between bone formation by osteoblasts and bone resorption by osteoclasts. The gut microbiota contributes to this axis by producing metabolites such as short-chain fatty acids (SCFAs) and modulating systemic inflammation, which in turn can affect bone cell activity and mineralization processes. The immune system participates through cytokine signaling that either promotes or inhibits bone resorption and formation, linking inflammation to bone health. Meanwhile, the nervous system, via autonomic and sensory pathways, regulates nutrient absorption, bone blood flow, and directly modulates bone cell function through neuropeptides and neurotransmitters. Hormonal factors, including parathyroid hormone, sex steroids, and gut-derived hormones like serotonin, further modulate bone turnover by fine-tuning osteoblast and osteoclast activity. Disruptions in any component of this axis, such as dysbiosis of the gut microbiota, chronic inflammation, neurotransmitter imbalance, or hormonal deficiencies can lead to dysregulated bone remodeling, favoring increased bone resorption, decreased bone formation, and eventually decreased bone density. This manifests clinically as osteoporosis, characterized by fragile bones and elevated fracture risk. Therefore, understanding and targeting the brain-gut-bone axis presents promising therapeutic opportunities. Interventions such as probiotics, anti-inflammatory therapies, neuromodulation, and hormone replacement can potentially restore the balance in this axis, improving bone health and reducing osteoporosis progression. This integrative approach highlights the importance of systemic interactions and opens new avenues for precision medicine in bone metabolic disorders.


  • Clinical outcomes of infliximab treatment in hospitalized patients with severe COVID-19; a parallel, double-blind, randomized controlled trial

    by Akbar Soleymani Babadi, Mahdi Ghatrehsamani, Jafar Majidi, Soleiman Kheiri, Mohammad Mousavi

    Introduction: This study aims to assess the effectiveness and safety of infliximab in hospitalized patients with severe COVID-19. Patients and Methods: This double blind, randomized controlled trial was conducted on 48 patients with COVID-19 at Hajar hospital in Shahrekord, Iran, from December 2020 to June 2021, to evaluate the efficacy and safety of infliximab in hospitalized patients with severe COVID-19. Eligible adults with confirmed severe COVID-19 were randomized to receive a single intravenous dose of infliximab (4 mg/kg) plus standard care (infliximab-treated group n = 24), or the control group (n = 24) received standard care alone. Data on demographics, clinical signs, radiologic findings, laboratory markers, and clinical outcomes were systematically collected at admission and during hospitalization. The primary outcomes included comparison of duration of hospital stay, mortality rate, mechanical ventilation requirement, and laboratory parameters between the two groups. Results: The results indicate that infliximab treatment in patients was associated with better clinical outcomes, including reduced hospital stay, lower mortality rates, decreased need for mechanical ventilation, and experiencing of better oxygen saturation. Laboratory parameters showed that the infliximab group experienced improved immune cell profiles marked by increased lymphocytes and decreased neutrophils and white blood cells. Additionally, inflammatory and coagulation markers such as D-dimer, lactate dehydrogenase (LDH), and C-reactive protein (CRP) were more effectively reduced in the infliximab-treated group, reflecting better control of inflammation; however, infliximab treatment indicated no significant difference in platelet levels between groups. Conclusion: Infliximab treatment in COVID-19 patients is associated with improved clinical outcomes, highlighting its potential as an effective immunomodulatory therapy. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT20201229049873N1; https://irct.behdasht.gov.ir/trial/53791), and ethical code from Shahrekord University of Medical Sciences (IR.SKUMS.REC.1399.227; https://ethics.research.ac.ir/EthicsProposalView.php?id=169921).

  • Open Access

    Inflammatory impact of cigarette smoking on bone function and structure; a review of evidence

    by Yashar Shahbaz, Rasoul Shirmohammadi, Shirin Shamsghahfarokhi, Hooman Esfahani, Mobin Forghan, Hojjat Eghbali Jelodar, Leila Ashrafi, Mohammad Mousavi

    Cigarette smoking represents a major lifestyle risk factor for bone loss and skeletal disorders, with complex etiological mechanisms consisting both direct tissue effects and systemic alterations. Recent evidence demonstrates that tobacco smoking triggers an intricate cascade of cellular and molecular events that disrupts the delicate balance of bone remodeling, finally leading to decreased bone mass and increased fracture risk.


  • A systematic review and meta-analysis of the effect of statins on osteoporotic fractures

    by Shahin Asgari-Savadjani, Maryam Tavakoli Chaleshtori, Mohammad Mousavi

    Introduction: Statins can increase bone density and improve osteoporosis. As fractures are the worst outcome of osteoporosis, our study aimed to investigate the relationship between statins and osteoporotic fractures using a systematic review and meta-analysis. Materials and Methods: A systematic review and meta-analysis were conducted using the PRISMA checklist to draft this article. ProQuest, PubMed, Web of Science, Cochrane, and Google Scholar were searched to access sources without time restrictions until November 10, 2023. Data analysis was performed using STATA 14 software. Results: About 12 studies showed that statins generally reduced osteoporotic fractures (OR: 0.82; 95% CI: 0.72, 0.94). The association between statins and osteoporotic fractures in case-control studies (OR: 0.92; 95% CI: 0.76, 1.11), RCT studies (OR: 1.67; 95% CI: 0.86, 3.26), and cohort studies (OR: 0.70; 95% CI: 0.59, 0.83) was observed. The likelihood of osteoporotic fractures with the use of pravastatin (OR: 0.96; 95% CI: 0.87, 1.07), fluvastatin (OR: 0.88; 95% CI: 0.75, 1.03), atorvastatin (OR: 0.92; 95% CI: 0.76, 1.10), rosuvastatin (OR: 0.85; 95% CI: 0.66, 1.08), and simvastatin (OR: 0.98; 95% CI: 0.92, 1.03) was noted. Additionally, statins led to a reduction in vertebral fractures (OR: 0.74; 95% CI: 0.65, 0.86) but showed no effect on the hip region (OR: 0.78; 95% CI: 0.60, 1.01). In the groups of 30–364 cumulative defined daily doses (cDDD) (OR: 0.84; 95% CI: 0.65, 1.08) and ≥365 cDDD (OR: 0.50; 95% CI: 0.25, 1), no significant association was observed between statins and osteoporotic fractures. Conclusion: Overall, statins resulted in an 18% reduction in the risk of osteoporotic fractures. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023484864) and Research Registry (UIN: reviewregistry1750) website.


  • Interleukin-21 Receptor Might be a Novel Therapeutic Target for the Treatment of Rheumatoid Arthritis

    by Farhad Seif, Majid Khoshmirsafa, Mohammad Mousavi, Pezhman Beshkar, Mahmoud Rafeian-Kopaei, Nader Bagheri, Hedayatollah Shirzad